Sequana Medical NV (EBR:SEQUA)

Belgium flag Belgium · Delayed Price · Currency is EUR
0.7100
-0.0120 (-1.66%)
Oct 30, 2025, 1:30 PM CET
-1.66%
Market Cap43.61M
Revenue (ttm)n/a
Net Income (ttm)-51.85M
Shares Out60.40M
EPS (ttm)-1.11
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume130,409
Average Volume324,633
Open0.7160
Previous Close0.7220
Day's Range0.7050 - 0.7190
52-Week Range0.6460 - 4.3900
Beta-0.09
RSI32.40
Earnings DateDec 15, 2025

About Sequana Medical NV

Sequana Medical NV develops and commercializes treatments for patients with diuretic-resistant fluid overload in liver disease, cancer, and heart failure in Belgium, Germany, France, and internationally. The company offers alfapump system, an implantable pump system for the treatment of refractory liver ascites and malignant ascites; and Direct Sodium Removal (DSR) for the treatment of fluid overload spread across the body. Sequana Medical NV was founded in 2006 and is headquartered in Gent, Belgium. [Read more]

Sector Healthcare
Founded 2006
Employees 48
Stock Exchange Euronext Brussels
Ticker Symbol SEQUA
Full Company Profile

Financial Performance

In 2024, Sequana Medical NV's revenue was 105,500, a decrease of -85.19% compared to the previous year's 712,173. Losses were -44.65 million, 37.1% more than in 2023.

Financial Statements